| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/16/2007 | US7163946 Urogenital disorders; bleeding; hormone replacement therapy; anticancer agents; contraceptives |
| 01/16/2007 | US7163945 to treat inflammatory diseases and disorders associated with inflammation, preferably vascular diseases and disorders |
| 01/16/2007 | US7163944 Cyclic diamine compound and pharmaceutical containing the same |
| 01/16/2007 | US7163943 e.g., 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3 ,5]triazine-2,4-diamine; inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells and inhibit smooth muscle proliferation. |
| 01/16/2007 | US7163942 Sulfonamide compounds for the treatment of neurodegenerative disorders |
| 01/16/2007 | US7163941 Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| 01/16/2007 | US7163940 Pyrazolopyridinyl pyrimidine therapeutic compounds |
| 01/16/2007 | US7163939 important in the progression of many disease states that are induced by the inappropriate proliferation of cells; anticancer agent |
| 01/16/2007 | US7163938 Substituted carboxamides |
| 01/16/2007 | US7163937 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/16/2007 | US7163936 β-lactam compounds and process for producing the same |
| 01/16/2007 | US7163935 Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same |
| 01/16/2007 | US7163934 Methods for treating delirium glucocorticoid receptor-specific antagonists |
| 01/16/2007 | US7163933 Treating agent for Paget's disease of bone |
| 01/16/2007 | US7163932 Aryldifluoromethylphosphonic acids for treatment of diabetes |
| 01/16/2007 | US7163931 Compositions of estrogen-cyclodextrin complexes |
| 01/16/2007 | US7163930 Pharmaceutical compositions and methods relating to fucans |
| 01/16/2007 | US7163929 Methods and compositions for treating flaviviruses and pestiviruses |
| 01/16/2007 | US7163928 Partial and full agonists of A1 adenosine receptors |
| 01/16/2007 | US7163927 Gene expression inhibition; treating cancer and autoimmune diseases |
| 01/16/2007 | US7163924 antibacterial activity in humans and mammals; semi-synthetic |
| 01/16/2007 | US7163919 injecting into the tumor itself of a patient with a daily dose of between 1 and 5 mg of composition of citric acid, zinc, albumin and carrier |
| 01/16/2007 | US7163824 Cell containing nucleic acid molecule comprising polynucleotide sequence encoding engineered zinc finger protein operably linked to promoter, contacting target site in endogenous cellular gene with protein to inhibit transcription |
| 01/16/2007 | US7163808 Method for selectively delivering agent to arterial smooth muscle cells in mammal comprising administering agent and substance which selectively binds arterial smooth muscle cell-specific surface molecule selected from ephrin family |
| 01/16/2007 | US7163704 Injection made from Ixeris Sonchifolia Hance for treatment of cardio-cerebral vascular diseases and fundus diseases and method of producing thereof |
| 01/16/2007 | US7163703 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 01/16/2007 | US7163702 Process for isolating sea cucumber saponin Frondoside A, and immunomodulatory methods of use |
| 01/16/2007 | US7163699 Progestin co-micronized with a surfactant pharmaceutical composition comprising same methods for making same and uses thereof |
| 01/16/2007 | US7163698 Complex of drug and polyester |
| 01/16/2007 | US7163689 Administering intravenous valproate such that acute migraine headache is lessened or reduced in subject, wherein about 250 mg to 750 mg of valproate is administered to a subject over 30 minutes to 1 hour |
| 01/16/2007 | US7163677 Cationic polymers having degradable crosslinks |
| 01/16/2007 | US7163676 Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |
| 01/16/2007 | US7163672 Comprising an alkyl-polyglycoside surfactant and a medicament for inhalation |
| 01/16/2007 | CA2350713C Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body |
| 01/16/2007 | CA2349565C Process for preparing oral calcium compositions |
| 01/16/2007 | CA2326662C Therapeutic system which can be moisture-activated |
| 01/16/2007 | CA2294482C Treatment of aging skin |
| 01/16/2007 | CA2272308C Use of low molecular weight amino alcohols in ophthalmic compositions |
| 01/16/2007 | CA2266763C Use of at least one hydroxystilbene in a composition designed to encourage exfoliation of the skin, and composition containing it |
| 01/16/2007 | CA2257234C Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 01/16/2007 | CA2254755C Hexahydro-pyrido(4,3-b)indole derivatives as antipsychotic drugs |
| 01/16/2007 | CA2253453C Alkylaminobenzothiazole and -benzoxazole derivatives |
| 01/16/2007 | CA2252055C Fusogenic liposomes |
| 01/16/2007 | CA2219742C N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists |
| 01/16/2007 | CA2218981C Radicicol derivatives |
| 01/16/2007 | CA2212893C Prokinetic oxadiazoles |
| 01/16/2007 | CA2208746C Novel immunotherapeutic aryl amides |
| 01/16/2007 | CA2190882C The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process |
| 01/16/2007 | CA2190303C Pharmaceutical composition, method and device for preventing or treating dry eye or disease caused therefrom |
| 01/16/2007 | CA2182620C Improving glucose tolerance |
| 01/16/2007 | CA2174449C R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof |
| 01/16/2007 | CA2154533C Opthalmic preparation for use as artificial tear |
| 01/16/2007 | CA2111372C Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists |
| 01/13/2007 | CA2552273A1 An animal model for type ii diabetes mellitus and syndrome x and methods and uses thereof |
| 01/11/2007 | WO2007006036A2 Hydroxylated forms of ergosterols and ergocalciferols, derivatives thereof, methods of production and uses thereof |
| 01/11/2007 | WO2007006003A2 Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| 01/11/2007 | WO2007005991A1 Inhibitors of fibroblast activation protein alpha |
| 01/11/2007 | WO2007005962A2 Combinations of eszopiclone and an antidepressant |
| 01/11/2007 | WO2007005961A2 Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| 01/11/2007 | WO2007005951A2 Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| 01/11/2007 | WO2007005941A2 Liver targeted conjugates |
| 01/11/2007 | WO2007005940A2 Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| 01/11/2007 | WO2007005896A2 Anti-tubercular drugs: compositions and methods |
| 01/11/2007 | WO2007005879A2 Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| 01/11/2007 | WO2007005863A1 Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride |
| 01/11/2007 | WO2007005845A1 Mao-b inhibitors useful for treating obesity |
| 01/11/2007 | WO2007005785A1 Thiazoles derivatives as ampk activator |
| 01/11/2007 | WO2007005780A2 Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
| 01/11/2007 | WO2007005779A2 Antiviral agents |
| 01/11/2007 | WO2007005774A2 Novel derivatives of amino acids for treatment of obesity and related disorders |
| 01/11/2007 | WO2007005763A2 Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer |
| 01/11/2007 | WO2007005760A1 Methods of application of chemical compounds having therapeutic activities in treating cancers |
| 01/11/2007 | WO2007005758A2 Methods , compositions and devices for promoting angiogenesis |
| 01/11/2007 | WO2007005737A2 Amine oxidase inhibitors |
| 01/11/2007 | WO2007005720A2 Methods and compositions for promoting wound healing |
| 01/11/2007 | WO2007005716A2 Methods of treatment and compositions for use thereof |
| 01/11/2007 | WO2007005708A1 Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| 01/11/2007 | WO2007005673A1 Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
| 01/11/2007 | WO2007005670A2 Natural and synthetic sulfoxide, selenone and selenoxide analogs and polymer conjugated forms thereof for the modulation of angiogenesis |
| 01/11/2007 | WO2007005643A2 Novel aryloxyphenylpropanamines |
| 01/11/2007 | WO2007005631A1 Pyrrolotriazine compounds useful as kinase inhibitors |
| 01/11/2007 | WO2007005630A1 Pyrrolotriazine compounds useful as kinase inhibitors |
| 01/11/2007 | WO2007005603A2 Novel hydroxamic acid-containing amino acid derivatives |
| 01/11/2007 | WO2007005572A1 Process for synthesizing a cetp inhibitor |
| 01/11/2007 | WO2007005568A1 A-[(e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid analogs and method of manufacture and and use thereof |
| 01/11/2007 | WO2007005541A2 Small molecule inhibitors against west nile virus replication |
| 01/11/2007 | WO2007005510A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| 01/11/2007 | WO2007005503A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 01/11/2007 | WO2007005469A2 Method of enhanced benzoyl peroxide application |
| 01/11/2007 | WO2007005462A1 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same |
| 01/11/2007 | WO2007005453A2 Compositions for treating or preventing obesity and insulin resistance disorders |
| 01/11/2007 | WO2007005443A2 Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| 01/11/2007 | WO2007005404A1 AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
| 01/11/2007 | WO2007005403A1 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands |
| 01/11/2007 | WO2007005366A1 AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION |
| 01/11/2007 | WO2007005248A2 IMPROVED PROCESSES FOR THE PREPARATION OF PROTECTED -(+)-CATECHIN AND (-)-EPICATECHIN NOMOMERS, FOR COUPLING THE PROTECTED MONOMERS WITH AN ACTIVATED, PROTECTED EPICATECHIN MONOMER, AND FOR THE PREPARATION OF EPICATECHIN-(4β, 8)-EPICATECHIN OR -CATECHIN DIMERS AND THEIR DIGALLATES |
| 01/11/2007 | WO2007005214A1 Substituted {4(4-phenyl-piperazin-1yl)-cyclohexyl}-urea compounds |
| 01/11/2007 | WO2007005177A1 Alpha-2 adrenergic agonists for the treatment of pain |
| 01/11/2007 | WO2007005176A1 Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
| 01/11/2007 | WO2007005174A2 4- (3 -hydroxy- and 3-aminomethyl-cyclohexen-3-ylmethyl) 1, 3-dihydroimdazole-2-thione derivatives as alpha-2 adrenergic agonists |